TR60

TR60 is a revolutionary long-acting synthetic peptide invented by Eli Lilly, the world’s first dual agonist targeting both GLP‑1 and GIP receptors. This 39-amino-acid polypeptide is structurally modified with lipid side chains, which bind reversibly to human serum albumin and extend its half-life to around five days. Thanks to this design, patients only need one subcutaneous injection per week, bringing much higher compliance than daily metabolic drugs. Its molecular optimization also resists rapid breakdown by digestive enzymes, maintaining stable drug concentration in the human body. Two mainstream commercial versions are launched globally: MJ for type 2 diabetes treatment and ZB for chronic weight management. The dual-receptor activation mechanism distinguishes TR60 from single-target GLP‑1 peptides. In pancreatic tissues, it stimulates insulin secretion only when blood glucose rises and suppresses glucagon overproduction, which efficiently lowers blood sugar without high risks of hypoglycemia. It also enhances insulin sensitivity in the liver and muscles to ease long-term insulin resistance. In the gastrointestinal tract, it slows gastric emptying, flattens post-meal glucose surges and creates a lasting sense of fullness. Crossing the blood-brain barrier, the peptide acts on the hypothalamus to curb hunger and food cravings, cutting overall calorie intake. Different from many weight-loss drugs, TR60 mainly eliminates visceral fat instead of lean muscle mass, supporting sustainable and healthy weight reduction. Regulatory authorities including the FDA and EMA have issued clear clinical indications. MJ serves as auxiliary therapy for adults and teenagers over 10 years old with type 2 diabetes, combined with controlled diet and regular exercise. ZB is prescribed for obese adults with a BMI above 30, as well as overweight patients with hypertension, hyperlipidemia or sleep apnea. It is forbidden for patients with type 1 diabetes, diabetic ketoacidosis, personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2. A slow dose titration scheme guarantees safety. The initial weekly dose is 2.5 mg for four weeks to adapt the body. Users may raise the dosage by 2.5 mg every four weeks, capped at 15 mg per week for adults. Phase III SURPASS and SURMOUNT trials have proven its powerful effects. At the maximum dose, glycated hemoglobin can drop by up to 2.6%, and obese participants lose an average of 16–24 kg over 72 weeks, with over 40% losing more than 20% of their original body weight. Mild gastrointestinal issues such as nausea, dh and loss of appetite are the most common side effects, which usually fade after the dosage stabilizes. Rare severe risks include pancreatitis, gallstones and acute kidney injury caused by dehydration. When combined with insulin or sulfonylureas, doctors need to lower the dosage of hypoglycemic agents to avoid dangerous low blood sugar. Currently, researchers are exploring its value in treating NASH, PCOS and heart failure, making TR60 a core breakthrough peptide for global metabolic disorder treatment.